# Serotonin Receptor Blockers in Ischemic Mitral Regurgitation

Study · id `cardio:ct-nct05469165` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05469165](<https://clinicaltrials.gov/study/NCT05469165>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05469165

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 214 participants.

## Technical summary

Registry record NCT05469165. Randomized; quadruple masking; primary purpose prevention. Start 2023-06-20 (actual); primary completion 2026-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 214 participants (planned count; ClinicalTrials.gov record NCT05469165, source copy `cardio:ctgov-nct05469165-2023-11-15`, retrieved 2026-10-26)
- Started: 2023-06-20 (actual) (ClinicalTrials.gov record NCT05469165, source copy `cardio:ctgov-nct05469165-2023-11-15`, retrieved 2026-10-26)
- Primary completion: 2026-09 (anticipated) (ClinicalTrials.gov record NCT05469165, source copy `cardio:ctgov-nct05469165-2023-11-15`, retrieved 2026-10-26)
- Completion: 2027-09 (anticipated) (ClinicalTrials.gov record NCT05469165, source copy `cardio:ctgov-nct05469165-2023-11-15`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT05469165, source copy `cardio:ctgov-nct05469165-2023-11-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05469165-2023-11-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Serotonin Receptor Blockers in Ischemic Mitral Regurgitation
- Acronym: CYPRO-MR
- Condition: Ischemic Mitral Regurgitation
- Intervention (Drug): Cyproheptadine 4 Mg Oral Tablet
- Intervention (Other): Placebo
- Lead sponsor: Laval University
- Lead sponsor class: OTHER
- Collaborator: Canadian Institutes of Health Research (CIHR)
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Laval University (`cardio:org-laval-university`)
- Registry lists this organization as a collaborator: Canadian Institutes of Health Research (CIHR) (`cardio:org-canadian-institutes-of-health-research-cihr`)

## Provenance

Content hash: 5688f7bab32cd41dbd615d8f78ea2001cebc5e74fb5521221096a024bdeb25fc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
